Disorders of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent

Pediatric Endocrinology

Volumn , Issue , 2008, Pages 686-769

  Root, Allen W ^a,b   Diamond, Frank B ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882553803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604090-3.50022-3     Document Type: Chapter

References (523)

1. Kovacs CS Skeletal physiology: Fetus and neonate. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 50-55. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
2. Kovacs CS, Kronenberg HM Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocrine Reviews 1997, 18:832-872.
3. Kovacs CS, Kronenberg HM Skeletal physiology: Pregnancy and lactation. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 63-70. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
4. Naylor KE, Iqbal P, Fledelius C, et al. The effect of pregnancy on bone density and bone turnover. J Bone Mineral Res 2000, 15:129-137.
5. Black AJ, Topping J, Durham B, et al. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 2000, 15:557-563.
6. Koo WWK, Warren L Calcium and bone health in infants. J Neonat Nurs 2003, 22:23-35.
7. Weisman Y Maternal, fetal, and neonatal vitamin D and calcium metabolism during pregnancy and lactation. Endocrine Devel 2003, 6:34-49.
8. Hollis BW, Wagner CL Vitamin D requirements during lactation: High dose maternal supplementation as therapy to prevent hypovitaminosis D for the mother and nursing infant. Am J Clin Nutr 2004, 80:1752S-1758S.
9. Hollis BW, Wagner CL Nutritional vitamin D status during pregnancy: Reasons for concern. CMAJ 2006, 174:1287-1290.
10. Ziegler EE, Hollis BW, Nelson SE, Jeter JM Vitamin D deficiency in breast fed infants in Iowa. Pediatrics 2006, 118:603-610.
11. Holick MF Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006, 116:2062-2072.
12. Rigo J, De Curtis M, Pieltain C, et al. Bone mineral metabolism in the micropremie. Clin Perinatol 2000, 27:147-170.
13. Koo WWK, Hockman EM Physiologic predictors of lumbar spine bone mass in neonates. Pediatr Res 2000, 48:485-489.
14. Kovacs CS, Chafe LL, Fudge NJ, et al. PTH regulates fetal blood calcium and skeletal mineralization independently of PTHrP. Endocrinology 2001, 142:4983-4993.
15. Kovacs CS, Ho-Pao CL, Hunzelman JL, et al. Regulation of murine fetal-placental calcium metabolism by the calcium-sensing receptor. J Clin Invest 1998, 101:2812-2820.
16. 2+-sensing receptors in the human placenta. Placenta 2002, 23:192-200.
17. Moreau R, Daoud G, Bernatchez R, et al. Calcium uptake and calcium transporter expression by trophoblast cells from human term placenta. Biochim Biophys Acta 2002, 1564:325-332.
18. Rummens K, van Cromphaut SJ, Carmeliet G, et al. Pregnancy in mice lacking the vitamin D receptor: Normal maternal skeletal response, but fetal hypomineralization rescued by maternal calcium supplementation. Pediatr Res 2003, 54:466-473.
19. Hallak M, Cotton DB Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: assessment of amniotic fluid, blood and brain. Am J Obstet Gynecol 1993, 169:427-431.
20. Carpenter TO Neonatal hypocalcemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 224-227. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
21. Bagnoli F, Bruchi S, Garosi G, et al. Relationship between mode of delivery and neonatal calcium homeostasis. Eur J Pediatr 1990, 149:800-803.
22. Hsu SC, Levine MA Perinatal calcium metabolism: Physiology and pathophysiology. Semin Neonatol 2004, 9:23-36.
23. Favus MJ (ed). Primer on the metabolic bone diseases and disorders of mineral metabolism, Sixth edition. Washington, D.C.: American Society for Bone and Mineral Research 492, 496.
24. Koo WW, Hockman EM, Dow M Palm olein in the fat blend of infant formulas: Effect on the intestinal absorption of calcium and fat, and bone mineralization. J Am Coll Nutr 2006, 25:117-122.
25. Diamond FB, Root AW Factors regulating the adolescent growth spurt in females. Adol Pediatr Gynec 1992, 5:48-49.
26. Krabbe S Calcium homeostasis and mineralization in puberty. Danish Med Bull 1989, 36:113-124.
27. McKay CP, Specker BL, Tsang RC, Chesney RW Mineral metabolism during childhood. Disorders of bone and mineral metabolism 1992, 395-416. Raven Press, New York. F.L. Coe, M.J. Favus (Eds.).
28. Mora S, Pitukcheewanont P, Kaufman FR, et al. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14:1664-1671.
29. Root AW, Diamond FB Disorders of calcium and phosphorus metabolism in adolescents. Endocrinol Metab Clin NA 1993, 22:573-592.
30. Sorva R, Anttila R, Siimes MA, et al. Serum markers of collagen metabolism and serum osteocalcin in relation to pubertal development in 57 boys at 14 years of age. Pediatr Res 1997, 42:528-532.
31. Saggese G, Baroncelli GI, Bertelloni S, et al. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth retarded children. Pediatr Res 1994, 35:409-415.
32. Crofton PM, Wade JC, Taylor MRH, Holland CV Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxy-terminal telopeptide of type I collagen, and their interrelationships in school children. Clin Chem 1997, 43:1577-1581.
33. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover. J Clin Densitom 1999, 2:323-342.
34. Bollen A-M, Eyre DR Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994, 15:31-34.
35. Blumsohn A, Hannon RA, Wrate R, et al. Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol 1994, 40:663-670.
36. Nelson DA, Norris SA, Gilsanz V Skeletal physiology: Childhood and adolescence. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 55-63. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
37. Allgrove J Parathyroid disorders. Curr Paediatr 2001, 11:357-363.
38. Robertson WC Calcium carbonate consumption during pregnancy: An unusual cause of neonatal hypocalcemia. J Child Neurol 2002, 17:853-855.
39. Jain BK, Singh H, Singh D, Toor NS Phototherapy induced hypocalcemia. Indian Pediatr 1998, 35:566-567.
40. Foldenauer A, Vobeck S, Pohlandt F Neonatal hypocalcemia associated with rotavirus diarrhea. Eur J Pediatr 1998, 157:838-842.
41. Kurt A, Sen Y, Elkiran O, et al. Malignant infantile osteopetrosis: A rare cause of neonatal hypocalcemia. J Pediatr Endocrinol Metab 2006, 19:1459-1462.
42. Srinivasan M, Abinum M, Cant AJ Malignant infantile osteopetrosis presenting with neonatal hypocalcemia. Arch Dis Child Fetal Neonatal 2000, 83:F21-F23.
43. Holick MF Vitamin D deficiency. N Engl J Med 2007, 457:266-281.
44. 2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Human Molec Genet 1996, 5:601-606.
45. Shiohara M, Mori T, Mei B, et al. A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism. Eur J Pediatr 2004, 163:94-98.
46. Watanabe S, Fukumoto S, Chang H, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002, 360:692-694.
47. Mittleman SD, Hendy GN, Fefferman RA, et al. A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: Successful treatment with recombinant human parathyroid hormone. J Clin Endocrinol Metab 2006, 91:2474-2479.
48. Adachi M, Tachibana K, Masuno M, et al. Clinical characteristics of children with hypoparathyroidism due to 22q11.2 microdeletion. Eur J Pediatr 1998, 157:33-38.
49. Yagi H, Furutani Y, Hamada H, et al. Role of TBX1 in human del22q11.2 syndrome. Lancet 2003, 362:1366-1373.
50. Brauner R, Le Harivel de Gonneville A, Kindermans C, et al. Parathyroid function and growth in 22q11 deletion syndrome. J Pediatr 2003, 142:504-508.
51. Moss EM, Batshaw ML, Solot CB, et al. Psychoeducational profile of the 22q11.2 microdeletion: A complex pattern. J Pediatr 1999, 134:193-198.
52. Sobin C, Kiley-Brabeck K, Dale K, et al. Olfactory disorder in children with 22q11 deletion syndrome. Pediatrics 2006, 118:697-703.
53. Robin NH, Shprintzen RJ Defining the clinical spectrum of deletion 22q11.2. J Pediatr 2005, 147:90-96.
54. Shooner KA, Rope AF, Hopkin RJ, et al. Genetic analyses in two extended families with deletion 22q11 syndrome: Importance of extracardiac manifestations. J Pediatr 2005, 146:382-387.
55. Schinke M, Izumo S Getting to the heart of the DiGeorge syndrome. Nature Med 1999, 5:1120-1121.
56. Jerome LA, Papaioannou VE DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nature Genet 2001, 27:286-291.
57. Paylor R, Glaser B, Mupo A, et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci USA 2006, 103:7729-7734.
58. Moon AM Mouse models for investigating the developmental basis of human birth defects. Pediatr Res 2006, 59:749-755.
59. Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000, 406:419-422.
60. Watanabe T, Mochizuki H, Kohda N, et al. Autosomal dominant familial hypoparathyroidism and sensorineural deafness without renal dysplasia. Eur J Endocrinol 1998, 139:631-634.
61. Chiu W-Y, Chen H-W, Chao H-W, et al. Identification of three novel mutations in the GATA3 gene responsible for familial hypoparathyroidism and deafness in Chinese families. J Clin Endocrinol Metab 2006, 91:4587-4592.
62. Nesbit MA, Bowl MR, Harding B, et al. Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J Biol Chem 2004, 279:22624-22634.
63. Hershkovitz E, Parvari R, Diaz GA, Gorodischer R Hypoparathyroidism-retardation-dysmorphism (HRD) syndrome: A review. J Pediatr Endocrinol Metab 2004, 17:1583-1590.
64. Parvari R, Hershkovitz E, Grossman N, et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenney-Caffey syndrome. Nature Genet 2002, 32:448-452.
65. Courtens W, Wuyts W, Poot M, et al. Hypoparathyroidism-retardation-dysmorphism syndrome in a girl: A new variant not caused by a TBCE mutation, clinical report and review. Am J Med Genet 2006, 140:611-617.
66. Baumber L, Tufarelli C, Patel S, et al. Identification of a novel mutation disrupting the DNA binding activity of GCM2 in autosomal recessive familial isolated hypoparathyroidism. J Med Genet 2005, 42:443-448.
67. Ding C, Buckingham B, Levine MA Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest 2001, 108:1215-1220.
68. Thomee C, Schubert SW, Parma J, et al. GCMB mutation in familial isolated hypoparathyroidism with residual secretion of parathyroid hormone. J Clin Endocrinol Metab 2005, 90:2487-2492.
69. Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999, 84:3792-3796.
70. Bowl MR, Nesbit MA, Harding B, et al. An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. J Clin Invest 2005, 115:2822-2831.
71. Thakker RV Genetics of endocrine and metabolic disorders: Parathyroid. Rev Endocrinol Metab Dis 2004, 5:37-51.
72. Hoogendam J, Farih-Sips H, Wynaendts CW, et al. Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing Blomstrand osteochondrodysplasia type I and II. J Clin Endocrinol Metab 2007, 92:1088-1095.
73. Pinsker JE, Rogers W, McLean S, et al. Pseudohypoparathyroidism type 1a with congenital hypothyroidism. J Pediatr Endocrinol Metab 2006, 19:1049-1052.
74. Fujisawa Y, Yamashita K, Hirai N, et al. Transient late neonatal hypocalcemia with high serum parathyroid hormone. J Pediatr Endocrinol Metab 1997, 10:433-436.
75. Thakker RV Hypocalcemia: Pathogenesis, differential diagnosis, and management. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 213-215. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
76. Oskarsdottir S, Persson C, Eriksson BO, Fasth A Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr 2005, 164:146-153.
77. Bowen DC, Lederman HM, Sicherer SH, et al. Immune constitution of complete DiGeorge anomaly by transplantation of unmobilised blood mononuclear cells. Lancet 1998, 352:1983-1984.
78. Markert ML, Boeck A, Hale LP, et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med 1999, 341:1180-1189.
79. Langman CB Hypercalcemic syndromes in infants and children. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 209-212. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
80. Warner JT, Linton HR, Dunstan FDJ, Cartilidge PHT Growth and metabolic responses in preterm infants fed fortified human milk or a preterm formula. Intern J Clin Pract 1998, 52:236-240.
81. Fridriksson JH, Helmrath MA, Wessel JJ, Warner BW Hypercalcemia associated with extracorporeal life support in neonates. J Pediatr Surg 2001, 36:493-497.
82. Sharata H, Postellon DC, Hashimoto K Subcutaneous fat necrosis, hypercalcemia, and prostaglandin E. Pediatr Dermat 1995, 12:43-47.
83. Khan N, Licata A, Rogers D Intravenous bisphosphonate for hypercalcemia accompanying subcutaneous fat necrosis: A novel treatment approach. Clin Pediatr 2001, 40:217-219.
84. o)-sensing receptor (CaR): Roles in cell signaling and control of diverse cellular functions. Hormones and signaling 2000, 209-253. Academic Press, New York, . B. O'Malley (Ed.).
85. Chikatsu N, Fukumoto S, Suzawa M, et al. An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Clin Endocrinol 1999, 50:537-543.
86. Myashiro T, Kunii I, Manna TD, et al. Severe hypercalcemia in a 9-year-old Brazilian girl due to a novel inactivating mutation of the calcium-sensing receptor. J Clin Endocrinol Metab 2004, 89:5936-5941.
87. Brown EM Mutant extracellular calcium-sensing receptors and severity of disease. J Clin Endocrinol Metab 2005, 90:1246-1248.
88. Levine MA (2006). Spectrum of hyperparathyroidism in children. In Endocrine Society 88th Annual Meeting. [city]: Meet-The-Professor 390-396.
89. Steddon SJ, Cunningham J Calcimimetics and calcilytics: Fooling the calcium receptor. Lancet 2005, 365:2237-2239.
90. Sathasivam A, Garibaldi L, Murphy J Transient neonatal hyperparathyroidism: A presenting feature of mucolipidosis type II. J Pediatr Endocrinol Metab 2006, 19:859-862.
91. Nissenson RA Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia. Endocrinology 1998, 139:4753-4755.
92. Schipani E, Langman CB, Parfitt AM, et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 1996, 335:708-714.
93. Buckmaster A, Rodda C, Cowell CT, et al. The use of pamidronate in PTHrP associated hypercalcemia in infancy. J Pediatr Endocrinol Metab 1997, 10:301-304.
94. Selicorni A, Fratoni A, Pavesi MA, et al. Thyroid anomalies in Williams syndrome: Investigation of 95 patients. Am J Med Genet 2006, 140A:1098-1101.
95. Li DY, Faury G, Taylor DG, et al. Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest 1998, 102:1783-1787.
96. Morris CA, Mervis CB, Hobart HH, et al. GTF21 hemizygosity implicated in mental retardation in Williams syndrome: Genotype-phenotype analysis of five families with deletions in the Williams syndrome region. Am J Med Genet 2003, 123A:45-59.
97. Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-cotransporter NKCC2. Nature Genet 1996, 13:183-188.
98. Whyte MP Hypophosphatasia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 351-353. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
99. Mornet E Hypophosphatasia: The mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat 2000, 15:309-315.
100. Zurutuza L, Muller F, Ginrat JF, et al. Correlations of genotype and phenotype in hypophosphatasia. Hum Molec Genet 1999, 8:1039-1046.
101. Rice AM, Rivkees SA Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr 1991, 134:349-351.
102. Lteif AN, Zimmerman D Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998, 102:990-993.
103. Ezgu FS, Buyan N, Gunduz M, et al. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions. Eur J Pediatr 2004, 163:163-165.
104. Rauch F, Schoenau E Skeletal development in premature infants: A review of bone physiology beyond nutritional aspects. Arch Dis Child Fetal Neonatal Ed 2002, 86:F82-F85.
105. Beyers N, Alheit B, Taljaard JF, et al. High turnover osteopenia in preterm infants. Bone 1994, 15:5-13.
106. Miller ME The bone disease of preterm birth: A biomechanical perspective. Pediatr Res 2003, 53:10-15.
107. Funke S, Morava E, Czako M, et al. Influence of genetic polymorphisms on bone disease of preterm infants. Pediatr Res 2006, 60:607-612.
108. Atabek ME, Pirgon O, Yorulmaz A, Kurtoglu S The role of cord blood IGF-I levels in preterm osteopenia. J Pediatr Endocrinol Metab 2006, 19:253-257.
109. De Schepper J, Cools F, Vandenplas Y, et al. Whole body bone mineral content is similar at discharge in premature infants receiving fortified breast milk or preterm formula. J Pediatr Gastroenterol Nutr 2005, 41:230-234.
110. Cakir M, Mungan I, Karahan C, et al. Necrotizing enterocolitis increases the bone resorption in premature infants. Early Hum Devel 2006, 82:405-409.
111. Eliakim A, Shiff Y, Nemet D, Dolfin T The effect of neonatal sepsis on bone turnover in very-low birth weight preterm infants. J Pediatr Endocrinol Metab 2003, 16:413-418.
112. Aly H, Moustafa MF, Amer HA, et al. Gestational age, sex, and maternal parity correlate with bone turnover in premature infants. Pediatr Res 2005, 57:708-711.
113. Aladangady N, Coen PG, White MP, et al. Urinary excretion of calcium and phosphate in preterm infants. Pediatr Nephrol 2004, 19:1225-1231.
114. 4 in multiple pregnancies. J Pediatr Endocrinol Metab 2006, 19:1225-1230.
115. Shiff Y, Eliakim A, Shainkin-Kestenbaum R, et al. Measurement of bone turnover markers in premature infants. J Pediatr Endocrinol Metab 2001, 14:389-395.
116. Tsukahara H, Miura M, Hori C, et al. Urinary excretion of pyridinium cross-links of collagen in infancy. Metabolism 1996, 45:510-514.
117. Eliakim A, Nemet D Osteopenia of prematurity: The role of exercise in prevention and treatment. Pediatr Endocrinol Rev 2005, 2:675-682.
118. Nelson DA, Koo WWK Interpretation of absorptiometric bone mass measurements in the growing skeleton: Issues and limitations. Calcif Tissue Int 1999, 65:1-3.
119. Hammami H, Koo WWK, Hockman EM Body composition of neonates from fan beam duel energy X-ray absorptiometry measurements. J Parenteral Enteral Nutr 2003, 27:423-426.
120. Koo WWK, Walters J, Bush AJ, et al. Dual-energy x-ray absorptiometry studies of bone mineral status in newborn infants. J Bone Miner Res 1996, 11:997-1002.
121. Ritschl E, Wehmeijer K, de Terlizzi F, et al. Assessment of skeletal development in preterm and term infants by qualitative ultrasound. Pediatr Res 2005, 58:341-346.
122. Rubinacci A, Moro GE, Boehm G, et al. Quantitative ultrasound for the assessment of osteopenia in preterm infants. Europ J Endocrinol 2003, 149:307-315.
123. Littner Y, Mandel D, Mimouni FB, Dollberg S Bone ultrasound velocity of infants born small for gestational age. J Pediatr Endocrinol Metab 2005, 18:793-797.
124. McDevitt H, Tomlinson C, White MP, Ahmed SF Quantitative ultrasound assessment of bone in preterm and term neonates. Arch Dis Child Fetal Neonatal 2005, 90:F341-F342.
125. Aly H, Moustafa MF, Hassanein SM, et al. Physical activity combined with massage improves bone mineralization in premature infants: A randomized trial. J Perinatol 2004, 24:305-309.
126. Trotter A, Bokelmann B, Sorgo W, et al. Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement. J Clin Endocrinol Metab 2001, 86:601-603.
127. Trotter A, Maier L, Pohlandt F Calcium and phosphate balance of extremely preterm infants with estradiol and progesterone replacement. Am J Perinatol 2002, 19:23-29.
128. Fewtrell MS, Prentice A, Jones SC, et al. Bone mineralization and turnover in preterm infants at 8-12 years of age: The effect of early diet. J Bone Miner Res 1999, 14:810-820.
129. Ichiba H, Shintaku H, Fujimaru M, et al. Bone mineral density of the lumbar spine in very-low-birth-weight infants; a longitudinal study. Eur J Pediatr 2000, 159:215-218.
130. Weiler HA, Yuen CK, Seshia MM Growth and bone mineralization of young adults weighing less than 1500 grams at birth. Early Hum Devel 2002, 67:101-102.
131. Yeste D, Almar J, Clemente M, et al. Areal bone mineral density of the lumbar spine in 80 premature newborns: A prospective and longitudinal study. J Pediatr Endocrinol Metab 2007, 17:959-966.
132. Marini JC Osteogenesis imperfecta. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 418-421. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
133. Rauch F, Glorieux FH Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
134. Rauch F, Glorieux FH Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?. Ann Med 2005, 37:302-925.
135. Duval M, Fenneteau O, Doireau V, et al. Intermittent hemophagocytic lymphohistiocytois is a regular feature of lysinuric protein intolerance. J Pediatr 1999, 134:236-239.
136. Borsani G, Bassi MT, Sperandeo MP, et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nature Genet 1999, 21:297-301.
137. Whyte MP Sclerosing bone disorders. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 398-414. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
138. Fujita Y, Nakata K, Yasui N, et al. Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab 2000, 85:425-431.
139. Soliman AT, Rajab A, Al Salmi I, et al. Defective growth hormone secretion in children with pycnodysostosis and improved linear growth after growth hormone treatment. Arch Dis Child 1996, 75:242-244.
140. Carpenter TO, DeLucia MC, Zhang JH, et al. A randomized controlled study of the effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls. J Clin Endocrinol Metab 2006, 91:4866-4872.
141. Rude RK, Gruber HE Magnesium deficiency and osteoporosis: Animal and human observations. J Nutr Biochem 2004, 15:710-716.
142. Koo WWK Neonatal calcium, magnesium, and phosphorus disorders. Pediatric endocrinology 2007, 497-529. Informa Healthcare, New York. Fifth edition. F. Lifshitz (Ed.).
143. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genet 1996, 12:24-30.
144. Rude RK Magnesium depletion and hypermagnesemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 230-233. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
145. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nature Genet 2002, 31:171-174.
146. Chubanov V, Waldegger S, Mederos y Schnitzler M, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Nat Acad Sci USA 2004, 101:2894-2899.
147. 2+ resorption. Science 1999, 285:103-106.
148. Weber S, Schneider L, Peters M, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesaemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001, 12:1872-1881.
149. 2+ transport function of claudin-16. J Clin Invest 2006, 116:878-891.
150. Shalev H, Phillip M, Galil A, et al. Clinical presentation and outcome in primary familial hypomagnesemia. Arch Dis Child 1998, 78:127-130.
151. Konrad M, Schaller A, Seelow D, et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 2006, 79:949-957.
152. Shane E, Irani D Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 176-180. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
153. Domico MB, Huynh V, Anand SK, Mink R Severe hyperphosphatemia and hypocalcemic tetany after oral laxative administration in a 3-month-old infant. Pediatrics 2006, 118:1580-1583.
154. Arnold A, Horst SA, Gardella TJ, et al. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990, 86:1084-1087.
155. Karaplis AC, Lim SK, Baba H, et al. Inefficient membrane targeting, translocation, and proteolytic processing by signal peptidase of a mutant preproparathyroid hormone protein. J Biol Chem 1995, 270:1629-1635.
156. Parkinson DB, Thakker RV A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nature Genet 1992, 1:149-152.
157. Goswami R, Mohapatra T, Gupta N, et al. Parathyroid hormone gene polymorphism and sporadic idiopathic hypoparathyroidism. J Clin Endocrinol Metab 2004, 89:4840-4845.
158. Makita Y, Masuno M, Imaizumi K, et al. Idiopathic hypoparathyroidism in 2 patients with 22q11 microdeletions. J Med Genet 1995, 32:669.
159. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003, 88:4214-4220.
160. Tashjian AH, Chabner BA Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002, 17:1151-1161.
161. Kifor O, McElduff A, Leboff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004, 89:548-556.
162. Mayer A, Ploix C, Orgiazzi J, et al. Calcium-sensing receptor antibodies are relevant markers of acquired hypoparathyroidism. J Clin Endocrinol Metab 2004, 89:4484-4488.
163. Bringhurst FR, Demay MB, Kronenberg HM Hormones and disorders of mineral metabolism. Williams textbook of endocrinology 2003, 1303-1371. Saunders/Elsevier, Philadelphia. Tenth edition. P.R. Larsen, H.M. Kronenberg, S. Melmed, K.S. Plonsky (Eds.).
164. Goltzman D, Cole DEC Hypoparathyroidism. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 216-219. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
165. Eisenbarth GS, Gottlieb PA Autoimmune polyendocrine syndromes. N Engl J Med 2004, 350:2068-2079.
166. Betterle C, Greggio NA, Volpato M Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998, 83:1049-1055.
167. Perheentupa J Autoimmune polyendocrinopathy-candidasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
168. Wolff ASB, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: Phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007, 92:595-603.
169. Bjorses P, Halonen M, Palvimo JJ, et al. Mutations in the AIRE gene: Effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet 2000, 66:378-392.
170. Uchida D, Hatakeyama S, Matsushima A, et al. AIRE functions as an E3 ubiquitin ligase. J Exp Med 2004, 199:167-172.
171. Germain-Lee EL, Schwindinger W, Crane JL, et al. A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 2005, 146:4697-4709.
172. Levine MA Parathyroid hormone resistance syndromes. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 220-224. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
173. Farfel Z, Bourne HB, Iiri T The expanding spectrum of G protein diseases. N Engl J Med 1999, 340:1012-1020.
174. Weinstein LS, Liu J, Sakamoto A, et al. GNAS: Normal and abnormal functions. Endocrinology 2004, 145:5459-5464.
175. sa deficiency. J Clin Endocrinol Metab 2007, 92:1764-1768.
176. Gelfand IM, Eugster EA, DiMeglio LA Presentation and clinical progression of pseudohypoparathyroidism with multi-hormonal resistance and Albright hereditary osteodystrophy: A case series. J Pediatr 2006, 149:877-880.
177. sa leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J Bone Miner Res 2005, 20:663-671.
178. Aldred MA Genetics of pseudohypoparathyroidism types Ia and Ic. J Pediatr Endocrinol Metab 2006, 19:635-640.
179. Juppner H, Bastepe M Different mutations within or upstream of the GNAS locus cause distinct forms of pseudohypoparathyroidism. J Pediatr Endocrinol Metab 2006, 19:641-646.
180. Linglart A, Gensure RC, Olney RC, et al. A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type IB redefines the boundaries of the cis-acting imprinting control element of GNAS. Am J Hum Genet 2005, 76:804-814.
181. Wu W-I, Schwindinger WF, Aparicio LF, Levine MA Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G-alpha(s). J Biol Chem 2001, 276:165-171.
182. Perez de Nanclares G, Fernandez-Rebollo E, Santin I, et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 2007, 92:2370-2373.
183. Farfel Z, Iiri T, Shapira H, et al. Pseudohypoparathyroidism, a novel mutation in the beta/gamma-contact region of Gs-alpha impairs receptor stimulation. J Biol Chem 1996, 271:19653-19655.
184. Iiri T, Herzmark P, Nakamoto JM, et al. Rapid GDP release from Gs-alpha in patients with gain and loss of endocrine function. Nature 1994, 371:164-168.
185. Downs RW Miscellaneous causes of hypocalcemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 227-229. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
186. Bradley TJ, Metzger DL, Sanatani S Long on QT and low on calcium. Cardiol Young 2004, 14:667-670.
187. Gavalas NG, Kemp EH, Krohn KJE, et al. The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2007, 92:2107-2114.
188. Ishii T, Suzuki Y, Ando N, et al. Novel mutations of the autoimmune regulator gene in two siblings with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000, 85:2922-2926.
189. Cole DEC, Kooh SW, Vieth R Primary infantile hypomagnesemia: Outcome after 21 years and treatment with continuous nocturnal nasogastric magnesium infusion. Eur J Pediatr 2000, 159:38-43.
190. Marx SJ Familial hypocalciuric hypercalcemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 188-190.
191. Pidasheva S, Grant M, Canaff L, et al. Calcium-sensing receptor dimerizes in the endoplasmic reticulum: Biochemical and biophysical characterization of the CASR mutants retained intracellularly. Hum Molec Genet 2006, 15:2200-2209.
192. Pallais JC, Kifor O, Chen Y-B, et al. Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 2004, 351:362-369.
193. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81:1598-1606.
194. Bilezikian JP, Silverberg SJ Primary hyperparathyroidism. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 181-185. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
195. Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005, 115:974-980.
196. Marx SJ, Simonds WF Hereditary hormone excess: Genes, molecular pathways, and syndromes. Endocrine Reviews 2005, 26:615-661.
197. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN I gene in parathyroid tumors. Nature Genet 1997, 16:375-378.
198. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: Unexpected results and their implications. J Med Genet 2004, 41:155-160.
199. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genet 2002, 32:676-680.
200. Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: Clinical and genetic characteristics of 36 kindreds. Medicine 2002, 81:1-26.
201. Rubin MR, Silverberg SJ HRPT2 in parathyroid cancer: A piece of the puzzle. J Clin Endocrinol Metab 2005, 90:5505-5507.
202. Guarnieri V, Scillitani A, Muscarella LA, et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: Implication for cancer surveillance. J Clin Endocrinol Metab 2006, 91:2827-2832.
203. Krebs LJ, Shattuck TM, Arnold A HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005, 90:5015-5017.
204. Brandt ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
205. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias. Rec Prog Horm Res 1999, 54:397-438.
206. Root AW Genetic disorders of calcium and phosphorus metabolism. Crit Rev Clin Lab Sci 2000, 37:217-260.
207. Thakker RV Multiple endocrine neoplasia: Syndromes of the twentieth century. J Clin Endocrinol Metab 1998, 83:2617-2620.
208. Asgharian B, Turner ML, Gibril F, et al. Cutaneous tumors in patients with muliple endocrine neoplasm type 1 (MEN1) and gastrinomas: Prospective study of frequency and development of criteria with high sensitivity and specificity. J Clin Endocrinol Metab 2004, 89:5328-5336.
209. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96:143-152.
210. Kaji H, Canaff L, Lebrun J-J, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor beta signaling. Proc Natl Acad Sci 2001, 98:3837-3842.
211. Heppner C, Bilimoria KY, Agarwal SK, et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
212. Pannett AAJ, Thakker RV Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J Clin Endocrinol Metab 2001, 86:4371-4374.
213. Marx SJ, Agarwal SK, Kester MB, et al. Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). J Intern Med 1998, 243:447-453.
214. Turner JJO, Leotela PD, Pannett AAJ, et al. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2002, 87:2688-2693.
215. Kip 1 mutations. J Clin Endocrinol Metab 2007, 92:1948-1951.
216. Teh BT, Kytola S, Farnebo F, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998, 83:2621-2626.
217. Bassett JHD, Forbes SA, Pannett AAJ, et al. Characterization of mutations in patients with multiple endocrine neoplasia type I. Am J Hum Genet 1998, 62:232-244.
218. Stratakis CA, Ball DW A concise genetic and clinical guide to multiple endocrine neoplasias and related syndromes. J Pediatr Endocrinol Metab 2000, 13:457-465.
219. Santoro M, Melillo RM, Carlomagno F, et al. Molecular biology of the MEN2 gene. J Intern Med 1998, 243:505-508.
220. Lumbroso S, Paris F, Sultan C Activating Gsa mutations: Analysis of 113 patients with signs of McCune-Albright syndrome, a European collaborative study. J Clin Endocrinol Metab 2004, 89:2107-2113.
221. Cesur Y, Caksen H, Fundem A, et al. Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets. J Pediatr Endocrinol Metab 2003, 16:1105-1109.
222. Chan W, Sheehan S, Miller LC, Sadeghi-Najad A Hypercalcemia in a newly arrived international adoptee. J Pediatr Endocrinol Metab 2006, 19:1249-1250.
223. Holick MF, Shao Q, Liu WW, Chen TC The vitamin D content of fortified milk and infant formula. N Engl J Med 1992, 326:1178-1181.
224. Kawaguchi M, Mitsuhashi Y, Kondo S Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis. J Dermatol 2003, 30:801-804.
225. Ohigashi S, Tatsuno I, Uchida D, et al. Topical treatment with 22-oxacalcitriol (OCT), a new vitamin D analogue, caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy: A case report and analysis of the potential for hypercalcemia. Intern Med 2003, 42:1202-1205.
226. Adams JS, Hewison M Hypercalcemia caused by granuloma-forming disorders. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 200-202. American Society for Bone and Mineral Research, Washington, D.C., . Sixth edition. M.J. Favus (Ed.).
227. Jacobs TP, Bilezikian JP Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab 2005, 90:6316-6322.
228. Schurman SJ, Bergstrom WH, Root AW, et al. Interleukin-1 beta mediated calciotropic activity in serum of children with juvenile rheumatoid arthritis. J Rheumatol 1998, 25:161-165.
229. Mochizuki H, Saito M, Michigami T, et al. Severe hypercalcemia and respiratory insufficiency associated with infantile hypophosphatasia caused by two novel mutations of the tissue-nonspecific alkaline phosphatase gene. Eur J Pediatr 2000, 159:375-379.
230. Horwitz MJ, Stewart AF Hypercalcemia associated with malignancy. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 195-199. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
231. Kutluk MT, Hazar V, Akyuz C, et al. Childhood cancer and hypercalcemia: Report of a case treated with pamidronate. J Pediatr 1997, 130:828-831.
232. Wysolmerski JJ Miscellaneous causes of hypercalcemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 203-208. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
233. Prince RL Secondary and tertiary hyperparathyroidism. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 190-195. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
234. Bereket A, Casur P, Firat P, Yordam Y Brown tumour as a complication of secondary hyperparathyroidism in severe long-lasting vitamin D deficiency rickets. Eur J Pediatr 2000, 159:70-73.
235. Picca S, Cappa M, Rizzoni G Hyperparathyroidism during growth hormone treatment: A role for puberty?. Pediatr Nephrol 2000, 14:56-58.
236. Thomas SE, Stapleton FB Leave no stone unturned: Understanding the genetic bases of calcium-containing stones in children. Adv Pediatr 2000, 47:199-221.
237. Guise TA, Mundy GR Cancer and bone. Endocrine Reviews 1998, 19:18-54.
238. Solomon BL, Schaaf M, Smallridge RC Psychologic symptoms before and after parathyroid surgery. Am J Med 1994, 96:101-106.
239. Bornemann M Management of primary hyperparathyroidism in children. South Med J 1998, 91:475-476.
240. Ix JH, Quarles LD, Chertow GM Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not be modified. Nature Clin Pract Nephrol 2006, 2:337-339.
241. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am J Dis Child 1993, 147:270-273.
242. Pettifor JM Rickets and vitamin D deficiency in children and adolescents. Endocrinol Metab Clin NA 2005, 34:537-553.
243. Pettifor JM Nutritional and drug-induced rickets and osteomalacia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 330-338. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
244. Wharton B, Bishop N Rickets. Lancet 2003, 362:1389-1400.
245. Kreiter SR, Schwartz RP, Kirkman HN, et al. Nutritional rickets in African American breast-fed infants. J Pediatr 2000, 137:153-157.
246. Joiner TA, Foster C, Shope T The many faces of vitamin D deficiency rickets. Pediatr in Rev 2000, 21:296-302.
247. Schnadower D, Agarwal C, Oberfield SE, et al. Hypocalcemic seizures and secondary bilateral femoral fractures in an adolescent with primary vitamin D deficiency. Pediatrics 2006, 118:2226-2230.
248. Welch TR, Bergstrom WH, Tsang RC Vitamin D-deficient rickets: The reemergence of a once-conquered disease. J Pediatr 2000, 137:143-145.
249. Peng LF, Serwint JR A comparison of breastfed children with nutritional rickets who present during and after the first year of life. Clin Pediatr 2003, 42:711-717.
250. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004, 158:531-537.
251. Das G, Crocombe S, McGrath M, et al. Hypovitaminosis D among healthy adolescent girls attending an inner school. Arch Dis Child 2006, 91:569-572.
252. Kalkwarf HJ, Khoury JC, Lanphear BP Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in U.S. women. Am J Clin Nutr 2003, 77:257-265.
253. Hollis BW Circulating 25-hydroxyvitamin D levels indicative of vitamin D insufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005, 135:317-322.
254. Hollis B The determination of circulating 25-hydroxyvitamin D: No easy task. J Clin Endocrinol Metab 2004, 89:3149-3151.
255. DeLucia MC, Mitnick ME, Carpenter TO Nutritional rickets with normal circulating 25-hydroxyvitamin D: A call for reexamining the role of dietary calcium intake in North American infants. J Clin Endocrinol Metab 2003, 88:3539-3545.
256. Baroncelli GI, Bertelloni S, Ceccarelli C, et al. Bone turnover in children with vitamin D deficiency rickets before and during treatment. Acta Paediatr 2000, 89:513-518.
257. Misra M, Pacaud D, Petryk A, et al. (2007). Nutritional rickets and its management: Review of current knowledge and recommendations. Lawson Wilkins Pediatric Endocrine Society, personal communication to members.
258. Tangpricha V Vitamin D deficiency in the southern United States. South Med J 2007, 100:384-385.
259. Thacher TD, Ighogboja SI, Fischer PR Rickets without vitamin D deficiency in Nigerian children. Ambulatory Child Health 1997, 3:56-64.
260. Casella SJ, Reiner BJ, Chen TC, et al. A possible genetic defect in 25-hydroxylation as a cause of rickets. J Pediatr 1994, 124:929-932.
261. Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that human CYPR1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 2004, 101:7711-7715.
262. Demay MB Rickets caused by impaired vitamin D activation and hormone resistance: Pseudovitamin D deficiency rickets and hereditary vitamin D-resistant rickets. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 338-341. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
263. Miller WL, Portale AA Genetic disorders of vitamin D biosynthesis. Endocrinol Metab Clin NA 1999, 28:825-840.
264. Malloy PJ, Pike JW, Feldman D The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocrine Reviews 1999, 20:156-188.
265. Skorija K, Cox M, Sisk JM, et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 2005, 19:855-862.
266. Nicolaidou P, Tsitsika A, Papadimitriou A, et al. Hereditary vitamin D-resistant rickets in Greek children: Genotype, phenotype, and long-term response to treatment. J Pediatr Endocrinol Metab 2007, 20:425-430.
267. Li YC, Pirro AE, Amling M, et al. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II. Proc Natl Acad Sci USA 1997, 94:9831-9835.
268. Amling M, Priemel M, Holzmann T, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
269. Hewison M, Rut AR, Kristjansson K, et al. Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol 1993, 39:663-670.
270. Chen H, Hewison M, Hu B, Adams JS Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance. Proc Natl Acad Sci USA 2003, 100:6109-6114.
271. Carpenter TO New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin NA 1997, 44:443-446.
272. Sabbagh Y, Carpenter TO, Demay M Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA 2005, 102:9637-9642.
273. Alon US Hypophosphatemic vitamin D-resistant rickets. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 342-345. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
274. 3 down-regulates expression of PHEX, a marker of the mature osteoblast. Endocrinology 1999, 140:1192-1199.
275. Filisetti D, Ostermann G, von Bredow M, et al. Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues. Eur J Hum Genet 1999, 7:615-619.
276. Sato K, Tajima T, Nakae J, et al. Three novel PHEX gene mutations in Japanese patients with X-linked hypophosphatemic rickets. Pediatr Res 2000, 48:536-540.
277. Sabbagh Y, Boileau G, Campos M, et al. Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 2003, 88:2213-2222.
278. Cho HY, Lee BH, Kang JH, et al. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 2005, 58:329-333.
279. Holm IA, Nelson AE, Robinson BG, et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2001, 86:3889-3899.
280. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
281. White KE, Larsson TE, Econs MJ The roles of specific genes implicated as circulating factors in normal and disordered phosphate homeostasis: Frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocrine Reviews 2006, 27:221-241.
282. Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004, 35:455-462.
283. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblast growth factor-23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
284. Burnett SAM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
285. Liu S, Brown TA, Zhou A, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005, 16:1645-1653.
286. Goji K, Ozaki K, Sadewa AH, et al. Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait. J Clin Endocrinol Metab 2006, 91:365-370.
287. Novais E, Stevens PM Hypophosphatemic rickets: The role of hemiepiphysiodesis. J Pediatr Orthop 2006, 26:238-244.
288. Steendijk R, Hauspie RC The pattern of growth and growth retardation of patients with hypophosphatemic vitamin D-resistant rickets: A longitudinal study. Eur J Pediatr 1992, 151:422-427.
289. Verge CF, Lam A, Simpson JM, et al. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991, 325:1843-1848.
290. Makitie O, Doria A, Kooh SW, et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003, 88:3591-3597.
291. Wilson DM Growth hormone and hypophosphatemic rickets. J Pediatr Endocrinol Metab 2000, 13:993-998.
292. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 2001, 138:236-243.
293. Haffner D, Nissel R, Wuhl E, Mehls O Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 2004, 113:e593-e596.
294. Baroncelli GI, Bertelloni S, Dati E, Cavallo L Linear growth during growth hormone treatment in X-linked hypophosphatemic rickets: Report of two patients. J Pediatr Endocrinol Metab 2007, 20:351-356.
295. Reid IR, Hardy DC, Murphy WA, et al. X-linked hypophosphatemia: A clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 1989, 68:336-352.
296. Reid IR, Murphy WA, Hardy DC, et al. X-linked hypophosphatemia: Skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 1991, 90:63-69.
297. Sullivan W, Carpenter T, Glorieux F, et al. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1992, 75:879-885.
298. Takeda E, Yamamoto H, Nashiki K, et al. Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 2004, 8:191-200.
299. Econs MJ, McEnery PT Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997, 82:674-681.
300. Jan de Beur SM, Levine MA Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 2002, 87:2467-2473.
301. Zeger MD, Adkins D, Fordham LA, et al. Hypophosphatemic rickets in opsismodysplasia. J Pediatr Endocrinol Metab 2007, 20:79-86.
302. Carpenter TO, Ellis BK, Insogna KL, et al. Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005, 90:1012-1020.
303. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91:2055-2061.
304. Ward LM, Rauch F, White KE, et al. Resolution of severe, adolescent-onset hypophosphatemic rickets following removal of an FGF-23-producing tumour of the distal ulna. Bone 2004, 34:905-911.
305. Shulman DI, Hahn G, Benator R, et al. Tumor-induced rickets: Usefulness of MR gradient echo recall imaging for tumor localization. J Pediatr 2004, 144:381-385.
306. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genet 2006, 38:1310-1315.
307. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nature Genet 2006, 38:1248-1250.
308. Zaidi M Skeletal remodeling in health and disease. Nature Med 2007, 13:791-801.
309. Ling Y, Ross HF, Myers ER, et al. DMP1 depletion decreases bone mineralization in vivo: An FTIR imaging analysis. J Bone Miner Res 2005, 20:2169-2177.
310. Bergwitz C, Roslin NM, Tieder M, et al. SLC4A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaP(1)-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006, 78:179-192.
311. Ichikawa S, Sorenson AH, Imel EA, et al. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006, 91:4022-4027.
312. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG Genetic disorders of renal electrolyte transport. N Engl J Med 1999, 340:1177-1187.
313. Tebben PJ, Thomas LF, Kumar R Fanconi syndrome and renal tubular acidosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 354-358. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
314. Ward LM Renal phosphate-wasting disorders in childhood. Pediatr Endocrinol Rev 2005, 2:342-350.
315. Oudet C, Martin-Coignard D, Pannetier S, et al. A second family with XLRH displays the mutation S244L in the CLCN5 gene. Hum Genet 1997, 99:781-784.
316. Zuruta L, Muller F, Gibrat JF, et al. Correlations of genotype and phenotype in hypophosphatasia. Hum Molec Genet 1999, 8:1039-1046.
317. Lia-Baldini AS, Muller F, Taillandier A, et al. A molecular approach to dominance in hypophosphatasia. Hum Genet 2001, 109:99-108.
318. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999, 14:2015-2026.
319. Barcia JP, Strife F, Langman CB Infantile hypophosphatasia: Treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization. J Pediatr 1997, 130:825-828.
320. Whyte MP, Mumm S, Deal C Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 2007, 92:1203-1208.
321. Stein P, Rosalki SB, Foo AY, Hjelm M Transient hyperphosphatasemia of infancy and early childhood: Clinical and biochemical features of 21 cases and literature review. Clin Chem 1987, 33:313-318.
322. Rosalki SB, Foo AY, Dooley JS Benign familial hyperphosphatasemia as a cause of unexplained increase in plasma alkaline phosphatase activity. J Clin Pathol 1993, 46:738-741.
323. Chong B, Hegde M, Fawkner M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: Relationships between phenotype and genotype. J Bone Miner Res 2003, 18:2095-2104.
324. Middleton-Hardie C, Zhu Q, Cundy H, et al. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res 2006, 21:438-445.
325. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002, 347:175-184.
326. Cundy T, Davidson J, Rutland M.D., et al. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005, 353:918-923.
327. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet 2000, 24:45-48.
328. Martin KJ, Al-Aly Z, Gonzalez EA Renal osteodystrophy. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 359-366. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
329. Rauch F Watching bones at work: what we can see from bone biopsies. Pediatr Nephrol 2006, 21:457-462.
330. Koch Nogueira PC, David L, Cochat P Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000, 14:342-346.
331. Sanchez CP, Salusky IB, Kuizon BD, et al. Bone disease in children undergoing successful renal transplantation. Kidney Int 1998, 53:1358-1364.
332. Reusz GS, Szabo AJ, Peter F, et al. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000, 83:146-151.
333. Nieto J, Ruiz-Cuervas P, Escuder A, et al. Tertiary hyperparathyroidism after renal transplantation. Pediatr Nephrol 1997, 11:65-68.
334. Bachrach LK Osteoporosis and measurement of bone mass in children and adolescents. Endocrinol Metab NA 2005, 34:521-535.
335. Harvey N, Earl S, Cooper C Epidemiology of osteoporotic fractures. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 244-248. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
336. Kalkwarf HJ, Zemel BS, Gilsanz V, et al. The bone mineral density in childhood study: Bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007, 92:2087-2099.
337. Ward KM, Ashby RL, Roberts SA, et al. UK reference data for the Hologic QDR Discovery dual-energy X-ray absorptiometry scanner in healthy children and young adults aged 6-17 years. Arch Dis Child 2007, 92:53-59.
338. Writing Group for ISCD Position Development Conference Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004, 7:17-26.
339. Zemel BS, Leonard MB, Kalkwarf HJ, et al. Reference data for whole body, lumbar spine and proximal femur for American children relative to age, gender and body size. J Bone Miner Res 2004, 19(1):S231.
340. Leonard MB, Shults J, Elliott DM, et al. Interpretation of whole body dual energy X-ray absorptiometry measures in children: Comparison with peripheral quantitative computed tomography. Bone 2004, 34:1044-1052.
341. Taylor A, Konrad PT, Norman ME, et al. Total body bone mineral density in young children: Influence of head bone mineral density. J Bone Miner Res 1997, 12:652-655.
342. Jones IE, Taylor RW, Williams SM, et al. Four-year gain in bone mineral in girls with and without past forearm fractures: A DEXA study. J Bone Miner Res 2002, 17:1065-1072.
343. Bachrach LK Making an impact on pediatric bone health. J Pediatr 2000, 136:137-139.
344. Golden NH Osteoporosis prevention: A pediatric challenge. Arch Pediatr Adolesc Med 2000, 154:542-543.
345. Ruiz JC, Mandel C, Garabedian M Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents. J Bone Miner Res 1995, 10:675-682.
346. Wyshak G Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med 2000, 154:610-613.
347. Tucker KL, Morita K, Qiao N, et al. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study. Am J Clin Nutr 2006, 84:936-942.
348. Janz KF, Burns TL, Torner JC, et al. Physical activity and bone measures in young children: The Iowa bone development study. Pediatrics 2001, 107:1387-1393.
349. Weiler HA, Janzen L, Green K, et al. Percent body fat and bone mass in healthy Canadian females 10 to 19 years of age. Bone 2000, 27:203-207.
350. Janicka A, Wren TAL, Sanchez MM, et al. Fat mass is not beneficial to bone in adolescents and young adults. J Clin Endocrinol Metab 2007, 92:143-147.
351. McKay HA, Petit MA, Schutz RW, et al. Augmented trochanteric bone mineral density after modified physical education classes: A randomized school-based exercise intervention study in prepubescent and early pubescent children. J Pediatr 2000, 136:156-162.
352. Petit MA, McKay HA, MacKelvie KJ, et al. A randomized school-based jumping intervention confers site and maturity-specific benefits on bone structural properties in girls: A hip structural analysis study. J Bone Miner Res 2002, 17:363-372.
353. Specker B, Binkley T Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year old children. J Bone Miner Res 2003, 18:885-892.
354. Lorentzon M, Mellstrom D, Haug E, Ohlsson C Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007, 92:497-503.
355. Weaver CM, Peacock M, Johnston CC Adolescent nutrition in the prevention of postmenopausal osteoporosis. J Clin Endocrinol Metab 1999, 84:1839-1843.
356. Winzenberg TM, Shaw K, Fryer J, Jones G Calcium supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews 2006, 2:CD005119.
357. Loro LM, Sayre J, Roe TF, et al. Early identification of children predisposed to low peak bone mass and osteoporosis later in life. J Clin Endocrinol Metab 2000, 85:3908-3918.
358. Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999, 84:4489-4496.
359. Stone M, Briody J, Kohn MR, et al. Bone changes in adolescent girls with anorexia nervosa. J Adolesc Hlth 2006, 39:835-841.
360. Misra M, Soyka LA, Miller KK, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2003, 88:3816-3822.
361. DiVasta AD, Gordon CM Bone health in adolescents. Adolesc Med 2006, 17:639-652.
362. Gordon NH, Lanzkowsky L, Schebendach J, et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002, 15:135-143.
363. Bourrin S, Ammann P, Bonjour JP, Rizzoli R Dietary protein restriction lowers plasma insulin-like growth factor I (IGF-I), impairs cortical bone formation, and induces osteoblastic resistance to IGF-I in adult female rats. Endocrinology 2000, 141:3149-3155.
364. Zacharin M Current advances in bone health of disabled children. Curr Opin Pediatr 2004, 16:545-551.
365. Henderson RC, Lark RK, Grka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002, 110:e5.
366. Henderson JK, Kairalla JA, Barrington JW, et al. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J Pediatr 2005, 146:769-775.
367. King W, Levin R, Schmidt R, et al. Prevalence of reduced bone mass in children and adults with spastic quadriplegia. Dev Med Child Neurol 2003, 45:12-16.
368. Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. J Pediatr 2002, 141:644-651.
369. Ali O, Shim M, Fowler E, et al. Growth hormone therapy improves bone mineral density in children with cerebral palsy: A preliminary pilot study. J Clin Endocrinol Metab 2007, 92:932-937.
370. Caulton JM, Ward KA, Alsop CW, et al. A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy. Arch Dis Child 2004, 89:131-135.
371. Chad KE, Bailey DA, McKay HA, et al. The effect of a weight-bearing physical activity program on bone mineral content and estimated volumetric density in children with spastic cerebral palsy. J Pediatr 1999, 135:115-117.
372. Finkelstein JS, Klibanski A, Neer RM A longitudinal evaluation of bone mineral density in adult men with histories of delayed adolescence. J Clin Endocrinol Metab 1996, 81:1152-1155.
373. Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998, 83:4280-4283.
374. Finkelstein JS, Klibanski A, Neer RM Evaluation of lumbar spine bone mineral density (BMD) using dual energy X-ray absorptiometry (DEXA) in 21 young men with histories of constitutionally-delayed puberty. J Clin Endocrinol Metab 1999, 84:3403-3404.
375. Moreira-Andres MN, Canizo FJ, de la Cruz FJ, et al. Bone mineral status in prepubertal children with constitutional delay of growth and puberty. Eur J Endocrinol 1998, 139:271-275.
376. Moreira-Andres MN, Canizo FJ, de la Cruz FJ, et al. Evaluation of bone mineral content in prepubertal children with constitutional delay of growth. J Pediatr Endocrinol Metab 2000, 13:591-597.
377. Reid IR Menopause. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 68-70. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
378. Manolagas SC Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Reviews 2000, 21:115-137.
379. Couse JF, Korach KS Estrogen receptor null mice: What have we learned and where will they lead us?. Endocrine Reviews 1999, 20:358-417.
380. Rubin K Turner syndrome and osteoporosis: Mechanisms and prognosis. Pediatrics 1998, 102:481-485.
381. Beckett PR, Copeland KC, Flannery TK, et al. Combination growth hormone and estrogen increase bone mineralization in girls with Turner syndrome. Pediatr Res 1999, 45:709-713.
382. Sas TC, De Muinck Keizer-Schrama SM, Stijnen T, et al. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol 2000, 52:531-536.
383. Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab 2003, 88:5717-5722.
384. Antoniazzi F, Bertoldo F, Lauriola S, et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin releasing hormone agonist treatment. J Clin Endocrinol Metab 1999, 84:1992-1996.
385. Van Staa TP The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006, 79:129-137.
386. Sambrook PN Glucocorticoid-induced osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 296-302. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
387. Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for initiation of fracture healing. Nature Genet 2006, 38:1424-1428.
388. Allen DB Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006, 53:101-110.
389. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
390. King JA, Wisniewski AB, Bankowski BJ, et al. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006, 91:865-869.
391. Noguera A, Ros JB, Pavia C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003, 16:529-536.
392. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocrine Reviews 2005, 26:688-703.
393. Ohlsson C, Bengtsson B-A, Isaksson OG, et al. Growth hormone and bone. Endocrine Reviews 1998, 19:55-79.
394. Maheshwari HG, Bouillon R, Nijs J, et al. The impact of congenital, severe, untreated growth hormone (GH) deficiency on bone size and density in young adults: Insights from genetic GH-releasing hormone receptor deficiency. J Clin Endocrinol Metab 2003, 88:2614-2618.
395. Lanes R, Gunczler P, Weisinger JR Decreased trabecular bone mineral density in children with idiopathic short stature: Normalization of bone density and increased bone turnover after 1 year of growth hormone treatment. J Pediatr 1999, 135:177-181.
396. Robson H, Siebler T, Shalet SM, Williams GR Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res 2003, 52:137-147.
397. Lucidarme N, Ruiz JC, Czernichow P, Leger J Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves disease. J Pediatr 2000, 137:56-62.
398. Tumer L, Hasanoglu A, Cinaz P, Bideci A Bone mineral density and metabolism in children treated with L-thyroxine. J Pediatr Endocrinol Metab 1999, 12:519-523.
399. Heap J, Murray MA, Miller MC, et al. Alterations in bone characteristics associated with glycemic control in type 1 diabetes mellitus adolescents. J Pediatr 2004, 144:56-62.
400. Moyer Mileur LJ, Dixon SB, Quick JL, et al. Bone mineral acquisition in adolescents with type 1 diabetes. J Pediatr 2004, 145:662-669.
401. Bechtold S, Dirlenbach I, Raile K, et al. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: Data using peripheral quantitative computed tomography. Pediatrics 2006, 118:627-634.
402. Atkinson SA, Halton JM, Bradley C, et al. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: Influence of disease, drugs and nutrition. Int J Cancer Suppl 1998, 11:35-39.
403. Hofbauer LC, Heufelder AE The role of receptor activator of Nuclear Factor-kB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000, 85:2355-2363.
404. Hoorweg-Nijman JJG, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol 1999, 50:237-244.
405. Cohen A, Ebling P, Sprague S, Shane E Transplantation osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 302-309. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
406. Barnes C, Wong P Egan B, et al. Reduced bone density among children with severe hemophilia. Pediatrics 2004, 114:e177-e181.
407. Buison AM, Kawchak DA, Schall JI, et al. Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics 2005, 116:943-949.
408. Gronowitz E, Mellstrom D, Strandvik B Normal annual increase of bone mineral density during two years in patients with cystic fibrosis. Pediatrics 2004, 114:435-442.
409. Rovner A, Zemel BS, Leonard MB, et al. Mild to moderate cystic fibrosis is not associated with increased fracture risk in children and adolescents. J Pediatr 2005, 147:327-331.
410. Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: An unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 2000, 85:2122-2126.
411. Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: Independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004, 19:1961-1968.
412. Van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
413. Cellier C, Flobert C, Cormier C, et al. Severe osteopenia in symptom-free adults with a childhood diagnosis of coeliac disease. Lancet 2000, 355:806.
414. Arpradi S, Horlick M, Shane E Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004, 89:21-23.
415. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004, 89:24-28.
416. Rouster-Stevens KA, Klein-Gitelman MS Bone health in pediatric rheumatic disease. Curr Opin Pediatr 2005, 17:703-708.
417. Rauch F, Bishop N Juvenile osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 293-296. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
418. Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005, 20:783-789.
419. Shaw NJ, Boivin CM, Crabtree NJ Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000, 83:143-145.
420. Ai M, Heeger S, Barteks CF, et al. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 2005, 77:741-753.
421. Balesman W, Van Hul W The genetics of low density Lipoprotein Receptor-Related Protein 5 in bone: A story of extremes. Endocrinology 2007, 148:2622-2629.
422. Glass DA, Karsenty G In vivo analysis of Wnt signaling in bone. Endocrinology 2007, 148:2630-2634.
423. Baron R, Rawadi G Targeting the Wnt/b-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
424. McDonnell DP The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999, 10:301-311.
425. Shaw NJ, Bishop NJ Bisphosphonate treatment of bone disease. Arch Dis Child 2005, 90:494-499.
426. Speiser PW, Clarkson CL, Eugster EA, et al. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev 2005, 3:87-96.
427. Rogers MJ From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2006, 75:451-461.
428. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003, 349:457-463.
429. Odvina CY, Zerwekh JE, Sudhaker R, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
430. Chan B, Zacharin M Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases. J Clin Endocrinol Metab 2006, 91:2020-2107.
431. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
432. Horwitz MJ, Tedesco MB, Grundberg C, et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:569-572.
433. Horwitz MJ, Tedesco MB, Sereika SM, et al. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: A dose escalation study. Osteoporosis Int 2006, 17:225-230.
434. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
435. Sambrook P, Cooper C Osteoporosis. Lancet 2006, 367:2010-2018.
436. Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nature Genet 2007, 39:359-365.
437. Byers PH Disorders of collagen biosynthesis and structure. The metabolic and molecular bases of inherited disease 1995, 4029-4077. McGraw-Hill, New York. Seventh edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Vale (Eds.).
438. Cabral WA, Makareeva E, Colige A, et al. Mutations near amino end of alpha-1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interfering with N-propeptide processing. J Biol Chem 2005, 280:19259-19269.
439. Marakeeva E, Cabral WA, Marini JC, Leikin S Molecular mechanism of alpha-1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: Unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. J Biol Chem 2006, 281:6463-6470.
440. Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291-304.
441. Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in lethal osteogenesis imperfecta. N Engl J Med 2006, 355:2757-2764.
442. Pepin M, Atkinson M, Starman BJ, Byers PH Strategies and outcomes of prenatal diagnosis for osteogenesis imperfecta: A review of biochemical and molecular studies completed in 129 pregnancies. Prenatal Diag 1997, 17:559-570.
443. Plotkin H Growth in osteogenesis imperfecta. Growth Genet Horm 2007, 23:17-23.
444. DiMeglio LA, Ford L, McClintock C, Peacock M Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004, 35:1038-1045.
445. Land C, Rauch F, Munns CF, et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone 2006, 39:901-906.
446. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005, 20:977-986.
447. DiMeglio LA, Peacock M Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006, 21:132-140.
448. Rauch F, Travers R, Glorieux FH Pamidronate in children with osteogenesis imperfecta: Histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006, 91:511-516.
449. Rauch F, Munns C, Land C, Glorieux FH Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab 2006, 91:1268-1274.
450. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003, 18:237-243.
451. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227-1231.
452. Chamberlain JR, Schwarze U, Wang P-R, et al. Gene targeting the stem cells from individuals with osteogenesis imperfecta. Science 2004, 303:1198-1201.
453. Prockop DJ Targeting gene therapy for osteogenesis imperfecta. N Engl J Med 2004, 350:2302-2304.
454. Collins MT, Bianco P Fibrous dysplasia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 415-418. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
455. sa mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 2006, 21(2):P120-P124.
456. Yamamoto T, Imanishi Y, Kinoshita E, et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Res 2005, 23:231-237.
457. Collins MT Spectrum and natural history of fibrous dysplasia of bone. J Bone Miner Res 2006, 21(2):P99-P104.
458. Glorieux FH, Rauch F, Collins MT Medical therapy of children with fibrous dysplasia. J Bone Miner Res 2006, 21(2):P110-P113.
459. Plotkin H, Rauch F, Zeitlin L, et al. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003, 88:4569-4575.
460. Tolar J, Teitelbaum SL, Orchard PJ Osteopetrosis. N Engl J Med 2004, 351:2839-2849.
461. Benichou OD, Laredo JD, De Vernejoul MC Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): Clinical and radiological manifestations in 42 patients. Bone 2000, 26:87-93.
462. Cleiren E, Benichou O, Van Hul E, et al. Albers Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in ClCN7 chloride channel gene. Hum Molec Genet 2001, 10:2861-2867.
463. Waguespack SG, Hui SL, DiMeglio LA, Econs MJ Autosomal dominant osteopetrosis: Clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 2007, 92:771-778.
464. Waguespack SG, Hui SL, White KE, et al. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab 2002, 87:2212-2217.
465. Rodan GA, Martin TJ Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
466. Doffinger S, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kB signaling. Nature Genet 2001, 27:277-285.
467. Dupuis-Girod S, Corradinin N, Hadj-Rabia S, et al. Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 2002, 109:1-6.
468. Sobacchi C, Frattini A, Orchard P, et al. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Molec Genet 2001, 10:1767-1773.
469. Susani L, Pangrazio A, Sobachhi A, et al. TCIRG1-dependent recessive osteopetrosis: Mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 2004, 24:225-235.
470. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
471. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC ClC-7 requires Ostm1 as a b-subunit to support bone resorption and lysosomal function. Nature 2006, 440:220-223.
472. Chalhoub N, Benachenhou N, Rajapurohitam V, et al. Grey-lethal mutation indices severe malignant autosomal recessive osteopetrosis in mouse and human. Nature Med 2003, 9:399-406.
473. Ramirez A, Faupel J, Goebel I, et al. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat 2004, 23:471-476.
474. Key LL, Rodriguez RM, Willi SM, et al. Recombinant human interferon gamma therapy for osteopetrosis. N Engl J Med 1995, 332:1594-1599.
475. Gao Y, Grassi F, Ryan MR, et al. IFN-g stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007, 117:122-132.
476. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
477. Ott SM Sclerostin and Wnt signaling: The pathway to bone strength. J Clin Endocrinol Metab 2005, 90:6741-6743.
478. Shoback D Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 2007, 92:747-753.
479. Patel MS, Karsenty G Regulation of bone formation and vision by LRP5. N Engl J Med 2002, 346:1572-1574.
480. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with increased bone density. Am J Hum Genet 2003, 72:763-771.
481. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis: Affected individuals and gene carriers. J Clin Endocrinol Metab 2005, 90:6392-6395.
482. Loots GB, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15:928-935.
483. Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati-Engelmann disease: Review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 2007, 43:1-11.
484. Janssens K, ten Dyke P, Janssens S, Van Hul W Transforming growth factor-beta 1 to the bone. Endocrine Reviews 2005, 26:743-774.
485. Whyte MP Extracellular (ectopic) calcification and ossification. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 436-437. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
486. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Molec Genet 2005, 14:385-390.
487. Ichikawa S, Imel EA, Sorensen AH, et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyltransferase domain of the GALNT3 gene. J Clin Endocrinol Metab 2006, 91:4472-4475.
488. Whyte MP Tumoral calcinosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 437-439. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
489. Araya K, Fukumoto S, Backenroth R, et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005, 90:5523-5527.
490. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis: Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
491. Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: A congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007, 22:235-242.
492. Garringer HJ, Fisher C, Larsson TE, et al. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 2006, 91:4037-4042.
493. Narchi H Hyperostosis with hyperphosphatemia: Evidence of familial occurrence and association with tumoral calcinosis. Pediatrics 1997, 99:745-748.
494. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet 2006, 38:525-527.
495. Kaplan FS, Fiori J, Serrano de la Pena L, et al. Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva. Ann NY Acad Sci 2006, 1068:54-65.
496. Bowers RR, Kim JW, Otto TC, Lane MD Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: Role of the BMP-4 gene. Proc Natl Acad Sci USA 2006, 103:13022-13027.
497. Kaplan FS, Glaser DL, Shore EM, et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg 2007, 89:347-357.
498. Chan I, Hamada T, Hardman C, et al. Progressive osseous heteroplasia resulting from a new mutation in the GNAS1 gene. Clin Exper Dermatol 2004, 29:77-80.
499. Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002, 346:99-106.
500. Shohat M, Rimoin DL The skeletal dysplasias. Pediatric endocrinology 2007, 145-162. Informa Health Care, New York. Fifth edition. F. Lifschitz (Ed.).
501. Superti-Furga A, Unger S, the Nosology Group of the International Skeletal Dysplasia Society International nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet 2007, 143A:1-18. http://www.isds.ch.
502. Brook CGD, de Vries BBA Skeletal dysplasias. Arch Dis Child 1998, 79:285-289.
503. Horton WA Molecular pathogenesis of achondroplasia. Growth Genet Horm 2006, 22:49-54.
504. Heuertz S, Le Merrer M, Zabel B, et al. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. Eur J Hum Genet 2006, 14:1240-1247.
505. Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single gene disorder from maternal plasma. Lancet 2000, 356:1170-1171.
506. Toydemir RM, Brassington AE, Bayrack-Toydemir P, et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 2006, 79:935-941.
507. Pitteloud N, Acierno JS, Meysing A, et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2006, 103:6281-6286.
508. Haque MF, King LM, Krakow D, et al. Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse. Nature Genet 1998, 20:157-162.
509. Belin V, Cusin V, Viot G, et al. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nature Genet 1998, 19:67-69.
510. Benito-Sanz S, Thomas NS, Huber C, et al. A novel class of pseudoautosomal region 1 deletions downstream of SHOX is associated with Leri-Weill dyschondrosteosis. Am J Hum Genet 2005, 77:534-544.
511. Marchini A, Marttila T, Winter A, et al. The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J Biol Chem 2004, 279:37103-37114.
512. Nissenson RA Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia. Endocrinology 1998, 139:4753-4755.
513. Thiel CT, Horn D, Zabel B, et al. Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. Am J Hum Genet 2005, 77:795-806.
514. Herman GE Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Molec Genet 2003, 12:R75-R88.
515. Opitz JM RSH (so-called Smith-Lemli-Opitz) syndrome. Curr Opin Pediatr 1999, 11:353-362.
516. Waterham HR, Koster J, Romeijn GJ, et al. Mutations in the 3 beta-hydroxysterol delta 24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69:685-694.
517. 14-reductase deficiency due to mutations in the lamin B receptor gene. Am J Hum Genet 2003, 72:1013-1017.
518. Levine B-S, Carpenter TO Evaluation and treatment of heritable forms of rickets. The Endocrinologist 1999, 9:358-365.
519. Hruska KA Hyperphosphatemia and hypophosphatemia. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 233-242. American Society for Bone and Mineral Research, Washington, D.C. Sixth edition. M.J. Favus (Ed.).
520. Sillence DO, Senn A, Danks DM Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979, 16:101-116.
521. Brown EM, Bai M, Ollak M Familial benign hypocalciuric hypercalcemia and other syndromes of altered responsiveness to extracellular calcium. Metabolic bone diseases 1997, 479-499. Academic Press, San Diego. Third edition. S.M. Krane, L.V. Avioli (Eds.).
522. 3 1α-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 1999, 84:4111-4117.
523. Kim CJ, Kaplan LE, Perwad F, et al. Vitamin D 1α-hydroxylase gene mutations in patients with 1α-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:3177-3182.